Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. By clicking "I agree" you agree to our use of cookies.

Novel Solutions in Oncology and Respiratory

In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. The foundation of Pieris’ partnerships and R&D efforts are Anticalin® molecules, a proprietary class of clinically-tested next generation therapeutic proteins.

Pieris in Immuno-oncology

Pieris has deployed its Anticalin drug discovery platform to identify first- and best-in-class multispecific drug candidates, including tumor-targeted T cell agonists and multi-checkpoint antagonists. Key components to the Company's IO franchise is a fully proprietary, targeted 4-1BB agonist; a strategic alliance with Servier with fully retained US rights on several programs; and an IO-focused R&D partnership with the world leading oncology company, Roche.

Pieris in Respiratory Diseases

Pieris is developing a diversified pipeline of inhaled Anticalin® molecules to locally address respiratory disease via inhalation and has established a transformative collaboration with AstraZeneca to access industry-leading formulation and device capabilities and accelerate the time to market of these drug candidates. The five-program, worldwide alliance provides co-development and co-commercialization options for Pieris' lead respiratory program, PRS-060, as well as two additional programs.